Drs. Nathaniel Chin, Cynthia Carlsson, Sterling Johnson Dive Into the Lecanemab Clinical Trials in Dementia Matters Video Exclusive

A graphic for a special episode of Dementia Matters, "A Closer Look at the Lecanemab Clinical Trials". Text has the title underneath the podcast logo and headshots of Drs. Nathaniel Chin, Cynthia Carlsson, and Sterling Johnson

Cynthia Carlsson, MD, MS, and Sterling Johnson, PhD, recently joined Nathaniel Chin, MD, on a special episode of the Dementia Matters podcast highlighting details and findings from the lecanemab phase 3 clinical trials. Carlsson and Johnson answered questions about the trials’ primary and secondary outcomes and the medication’s safety profile. They also discussed who was represented in the study and what happens going forward following this accelerated approval.

The U.S. Food and Drug Administration (FDA) approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of Alzheimer’s disease on January 6, 2023.

Watch the exclusive video interview on the Wisconsin ADRC YouTube page. An audio-only version will be available on all major podcast platforms and our website later this week.

Chin gave an overview of lecanemab’s clinical trial results in a previous episode of Dementia Matters published on January 17, 2023. The episode, titled “Introducing Lecanemab, the Latest Alzheimer’s Disease Drug to Receive FDA Accelerated Approval,” can be listened to on Spotify, Apple Podcasts, Podbean, our website, or wherever you listen to podcasts.